Trial Profile
A randomized, double-blind, single ascending dose study to evaluate the safety, tolerability, and pharmacokinetic profile of a Central Nervous System (CNS) compound in healthy participants
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Feb 2019
Price :
$35
*
At a glance
- Drugs Neuropsychotherapeutics (Primary)
- Indications Neurological disorders; Psychiatric disorders
- Focus Adverse reactions
- 05 Feb 2019 According to a Neurocrine Biosciences media release, the Company is currently analyzing the data from this study to inform the design of future clinical studies for the program.
- 16 Nov 2018 New trial record